Immunic (IMUX) Accumulated Expenses (2013 - 2026)

Immunic (IMUX) has 14 years of Accumulated Expenses data on file, last reported at $22.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 22.65% year-over-year to $22.4 million; the trailing twelve-month figure through Mar 2026 stood at $22.4 million (up 22.65% YoY), and the FY2025 full-year result was $18.6 million, up 44.39% from the prior year.
• Accumulated Expenses improved to $22.4 million in Q1 2026, from $18.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $22.4 million in Q1 2026 to a low of $5.7 million in Q2 2022.
• A 5-year average of $13.8 million and a median of $13.7 million in 2023 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses soared 133.71% in 2023 and plunged 30.81% in 2024, its largest moves.
• Tracing IMUX's Accumulated Expenses over 5 years: stood at $8.0 million in 2022, then surged by 133.71% to $18.7 million in 2023, then sank by 30.81% to $12.9 million in 2024, then soared by 44.39% to $18.6 million in 2025, then gained by 20.31% to $22.4 million in 2026.
• Business Quant data shows IMUX's Accumulated Expenses at $22.4 million in Q1 2026, $18.6 million in Q4 2025, and $19.5 million in Q3 2025.